STOCKS TELEGRAPH

Tag: APTX

  • Aptinyx Inc. (APTX) Witnesses Remarkable Recovery Amidst Challenges

    Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company specializing in brain and nervous system disorder treatments, is experiencing an astonishing after-market price surge.

    Despite a challenging day, the stock is making an epic recovery, soaring by an impressive 21% after hours. This unexpected jump is capturing attention and raising speculation about the factors driving Aptinyx Inc.’s remarkable after-market performance.

    Not all Hope is Lost for Aptinyx

    Aptinyx Inc. (APTX) faced a sell-off during the day, amid dissolution scares, dropping from $0.10 to $0.06. However, after hours, the stock experienced a significant rebound as bullish investors drove it back up to nearly $0.08.

    While the future remains uncertain, there are possibilities of a business combination or exploring alternative options instead of dissolution. With available funds and multiple scenarios on the table, APTX’s situation continues to be dynamic, attracting attention from investors seeking potential opportunities.

    APTX Milestone Challenges

    Aptinyx, earlier this year, faced challenges in its milestone update. The Phase 2b clinical study of NYX-783 for post-traumatic stress disorder (PTSD) did not show enough improvement to continue the program.

    Aptinyx engaged Ladenburg Thalmann as an advisor for strategic alternatives and implemented workforce reduction to cut costs. Another study with NYX-458 for cognitive impairment associated with Parkinson’s disease did not demonstrate meaningful improvements.

    However, the company is still pursuing the development of NYX-783 as a treatment for opioid use disorder (OUD), with ongoing research collaboration and funding from the National Institutes of Health (NIH).

    Conclusion

    The surge in the price of APTX is nothing short of remarkable. While uncertainties loom, Aptinyx remains resilient, exploring potential business combinations and alternatives.

    Despite setbacks, the company continues its pursuit of developing NYX-783 for opioid use disorder, supported by research collaboration and funding from the National Institutes of Health (NIH). Investors are closely watching APTX for potential opportunities amidst its dynamic situation.

  • Aptinyx Inc. (APTX) Stock Surges Inexplicably Amid Continuing Meme Stock Phenomenon Throughout Stock Market

    Aptinyx Inc. (APTX) Stock Surges Inexplicably Amid Continuing Meme Stock Phenomenon Throughout Stock Market

    Aptinyx Inc. (APTX) stock prices were up by a massive 28.7134% shortly after market trading commenced on June 11th, 2021, bringing the price per share up to USD$4.1317 early on in the trading day.

    Fortuitous Gains

    This surge in the value of the company’s equity comes despite a lack of significant news or recent developments that would help explain the overnight skyrocketing of the stock. With the meme stock phenomenon that rule the stock market this past week, it is possible the movement stems from a coordinated effort by retail investors to execute a short squeeze.

    Solid Liquidity Position

    In their financial reports for the first quarter of the fiscal year 2021, APTX reported a comfortable liquidity position with USD$146.8 million in cash and cash equivalents as of March 31st, 2021. This is an increase from the USD$141 million reported as of December 31st, 2020. With its current liquidity position, APTX anticipates its operations being funded through to 2023.

    Collaboration Revenue

    Revenue for the first quarter of the fiscal year 2021 came in at USD1 million, an improvement on the USD$0.8 million reported for the same time period of the prior fiscal year. The company’s revenue was generated from its research collaboration agreement with Allergan, a subsidiary of AbbVie. The funding of the company’s operations does not rely on the generation of these revenues.

    R&D Expenses

    Research and development costs were reported at USD$10.3 million for the first quarter of the fiscal year 2021, down from the USD$11.1 million reported for the same time period of the prior fiscal year. The year-over-year decrease is largely attributable to the completion of the exploratory Phase 2 study of NYX-783 in PTSD, having occurred in October 2020. Also contributing to the difference was the temporary suspension of enrollment in the exploratory Phase 2 study of NYX-458 in cognitive impairment, which went on to recommence in March 2021. The decrease was partially offset by the increasing of costs associated with the recommencement of the company’s two Phase 2b studies of NYX-2925 in chronic pain.

    Future Outlook for APTX

    Armed with a solid liquidity position that will see the company through the next several quarters, APTX is poised to push for the commercialization of its pipeline candidates. The company is keen to continue its trajectory of success and capitalize on the recent gains in equity value to ensure further organic growth. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Aptinyx Inc. (APTX) stock rises in the pre-market trading. Here’s to know why?

    Aptinyx Inc. (APTX) stock surged by 7.33% at the last trading close while the APTX stock continued to show gains by 1.86% in the pre-market trading as well after APTX announced that it has recommenced the screening of patients in a Phase 2 study of NYX-458. Aptinyx is a clinical-stage biopharmaceutical company that develops and commercializes patented synthetic small molecules for the cure of brain and nervous system disorders.

    What is happening?

    Today on April 6, 2021, APTX stock has reported that patient screening for a Phase 2 trial of NYX-458 in patients with moderate cognitive impairment, mild dementia associated with Parkinson’s disease, and dementia with Lewy bodies has started again. The results of this study are expected to be released in the second half of 2022, according to the company.

    NYX-458 is a novel oral NMDA receptor modulator that is currently being studied in clinical trials for the cure of cognitive dysfunction in Parkinson’s disease and dementia with Lewy bodies. In a design that is closely comparable to Parkinson’s disease in humans, NYX-458 has been shown to reverse cognitive deficits in nonhuman primates.

    Outlook of Phase 2 study

    The Phase 2 study is a randomized, double-blind, parallel-design, placebo-controlled trial in about 100 patients with moderate cognitive impairment or mild dementia linked with Parkinson’s disease or prodromal or indicate dementia with Lewy bodies to assess the safety and possible cognitive benefits of NYX-458.

    Over the course of 12-week duration, the study aims to compare daily oral dosing of NYX-458 30 mg to placebo. NYX-458’s overall safety and efficacy in patients will be assessed, as well as the drug’s possible cognitive benefits across various neurocognitive endpoints based on the concentration, memory, and executive function.

    Furthermore,

    The CEO of Aptinyx Norbert Riedel said that they are hoping for positive results from the evaluation of NYX-458 in patients who are suffering from cognitive impairment. He also added that current treatments for these patients often fail to provide significant results, and new treatment approaches are desperately needed. They also assume that NYX-458’s mechanism is ideally suited to solve these patients’ cognitive deficits, and they look forward to building on the convincing preclinical evidence we’ve gathered so far with NYX-458.